Clovis Oncology, Inc. (NASDAQ:CLVS) has been given an average rating of “Buy” by the twenty-one research firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $88.71.

CLVS has been the subject of a number of analyst reports. BidaskClub raised shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Monday, September 11th. Evercore ISI started coverage on Clovis Oncology in a report on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 target price on the stock. Royal Bank Of Canada started coverage on Clovis Oncology in a report on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 target price on the stock. Finally, SunTrust Banks, Inc. reiterated a “buy” rating on shares of Clovis Oncology in a report on Thursday, June 22nd.

Shares of Clovis Oncology (NASDAQ:CLVS) traded down 0.24% during midday trading on Wednesday, hitting $75.83. 197,666 shares of the stock were exchanged. The stock’s market cap is $3.71 billion. Clovis Oncology has a one year low of $25.50 and a one year high of $99.45. The stock’s 50-day moving average price is $73.35 and its 200 day moving average price is $69.15.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.02). The business had revenue of $14.62 million for the quarter, compared to the consensus estimate of $13.07 million. During the same period in the previous year, the company earned ($2.07) earnings per share. The company’s quarterly revenue was down 32.5% on a year-over-year basis. On average, analysts anticipate that Clovis Oncology will post ($7.56) earnings per share for the current year.

In related news, Director James C. Blair sold 18,450 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $78.61, for a total value of $1,450,354.50. Following the transaction, the director now owns 2,185 shares in the company, valued at $171,762.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $91.56, for a total value of $274,680.00. Following the completion of the transaction, the insider now owns 197,583 shares in the company, valued at approximately $18,090,699.48. The disclosure for this sale can be found here. Insiders sold 27,450 shares of company stock worth $2,143,685 in the last 90 days. 17.40% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. grew its holdings in Clovis Oncology by 0.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 20 shares during the last quarter. Hanseatic Management Services Inc. grew its holdings in Clovis Oncology by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 13,693 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 37 shares during the last quarter. Aperio Group LLC grew its holdings in Clovis Oncology by 1.7% during the second quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 83 shares during the last quarter. Clough Capital Partners L P grew its holdings in Clovis Oncology by 0.6% during the first quarter. Clough Capital Partners L P now owns 15,900 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 100 shares during the last quarter. Finally, Greenwood Capital Associates LLC grew its holdings in Clovis Oncology by 4.0% during the second quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 212 shares during the last quarter. Institutional investors own 99.03% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Clovis Oncology, Inc. (CLVS) Receives Average Recommendation of “Buy” from Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/20/clovis-oncology-inc-clvs-receives-average-recommendation-of-buy-from-analysts.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.